Birth Control Safe for PCOS Management Without Increasing Heart or Diabetes Risks, Landmark Study Finds

PHILADELPHIA — For decades, clinicians and patients navigating Polycystic Ovary Syndrome (PCOS) have walked a pharmacological tightrope, balancing the symptom-relieving benefits of hormonal contraceptives against fears of long-term metabolic harm. A groundbreaking clinical trial from the Perelman School of Medicine at the University of Pennsylvania may finally put those fears to rest.

The study, published in PLOS Medicine, reveals that oral birth control pills—whether taken alone or in combination with the diabetes drug metformin—do not increase the risk of metabolic syndrome in women with PCOS, even among those who are overweight or have a high Body Mass Index (BMI). Metabolic syndrome is a cluster of conditions, including high blood pressure and elevated blood sugar, that serve as a precursor to heart disease and type 2 diabetes.

These findings suggest that birth control remains a safe, effective “first-line” therapy, potentially allowing patients to simplify their treatment regimens and avoid the burdensome side effects of additional medications.

Understanding the PCOS Paradox

Polycystic Ovary Syndrome is a complex hormonal disorder affecting an estimated 5 to 6 million women in the United States alone. It is the leading cause of female infertility and is characterized by a communication breakdown between the brain’s hormones and the ovaries. This disruption causes the ovaries to overproduce androgens (male-type hormones), leading to a cascade of symptoms:

• Irregular or absent menstrual cycles

• Excessive facial and body hair (hirsutism) and severe acne

• Weight gain and difficulty losing weight

• Increased insulin resistance

While oral contraceptives (containing estrogen and progestin) are highly effective at regulating periods and lowering androgen levels, they have long carried a “black box” of concern for PCOS patients. Because these hormones can theoretically impact insulin sensitivity and blood pressure, many doctors feared that prescribing them to women who were already overweight would “fuel the fire” of cardiovascular risk.

To counter this perceived risk, physicians frequently co-prescribed metformin—a medication typically used for type 2 diabetes—to protect the patient’s metabolic health.

The COMET-PCOS Trial: A Closer Look at the Data

The “Comparison of Metformin and Ethinyl Estradiol/Norgestimate in PCOS” (COMET-PCOS) trial sought to determine if this multi-drug approach was truly necessary. Researchers enrolled 240 participants, all of whom had PCOS and an elevated BMI, and randomly assigned them to one of three groups for a 24-week period:

1. Oral Birth Control Pills alone

2. Metformin alone

3. A combination of both

Key Findings

The results challenged long-held assumptions in the medical community:

• No Increase in Metabolic Risk: At the end of the 24 weeks, the prevalence of metabolic syndrome was similar across all three groups. Birth control did not worsen the markers for heart disease or diabetes.

• Weight Neutrality (and Slight Improvement): Contrary to the common belief that birth control causes weight gain, women in the birth control group saw small reductions in total weight, waist circumference, and abdominal fat.

• The Metformin Struggle: Metformin alone did not significantly lower the risk of metabolic syndrome. Furthermore, participants in the metformin groups reported frequent gastrointestinal distress, including diarrhea, which led to many skipping doses.

“Our results can help guide treatment decisions right away,” said Anuja Dokras, MD, Ph.D., lead author of the study and director of the Penn Polycystic Ovary Syndrome Center. “Oral birth control remains a safe and effective first-line option… providers can prescribe it alone with greater peace of mind.”

Shifting the Focus to Quality of Life

For many women with PCOS, the “pill burden”—taking multiple medications with competing side effects—can be overwhelming. Dr. Dokras emphasized that this study empowers physicians to “simplify and personalize” care.

“Patients should also know birth control helped improve emotions and did not cause weight gain,” Dokras noted, highlighting that the psychological benefits of symptom management are just as vital as physical markers.

Outside experts agree that the study fills a critical gap in PCOS literature. While previous studies focused on single markers like “bad” cholesterol or fasting glucose, this trial looked at the comprehensive “metabolic syndrome” profile.

“This is a significant step forward in evidence-based care for PCOS,” says Sarah Mitchell, an endocrinology specialist not involved in the study. “We often see patients who are hesitant to start birth control because they’ve heard it causes weight gain or diabetes. This data provides the reassurance needed to prioritize symptom control without fear of metabolic fallout.”

Implications for Public Health and Future Research

The study’s findings could lead to a shift in clinical guidelines, favoring a more streamlined approach to PCOS management. By reducing the reliance on metformin unless specifically indicated for glucose intolerance, healthcare providers can improve patient adherence and reduce the incidence of gastrointestinal side effects.

However, researchers remain cautious. The study lasted 24 weeks, providing a snapshot of short-to-medium-term effects. Dr. Dokras noted that longer-term studies are essential to confirm these findings over several years and to measure specific impacts on mental health and hard cardiovascular events, such as heart attacks or strokes.

Additionally, future research will need to investigate whether these results are consistent across more diverse ethnic populations and various age groups, as PCOS can manifest differently depending on genetic background.

What This Means for You

If you are currently managing PCOS:

• Consult Your Provider: Discuss these findings with your gynecologist or endocrinologist to see if your current medication plan is optimized for your lifestyle.

• Monitor Holistically: While birth control is shown to be metabolically safe in this study, maintaining a balanced diet and regular exercise remains the cornerstone of PCOS health.

• Track Your Symptoms: Note changes in mood, skin, and cycle regularity, as these are key indicators of how well your treatment is working.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References and Sources

Primary Study:

• Dokras, A., et al. (2025). “Impact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial.” PLOS Medicine. DOI: 10.1371/journal.pmed.1004662